Clinical Trials Logo

Filter by:
NCT ID: NCT05745792 Active, not recruiting - Immune Tolerance Clinical Trials

Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity

CarTo-Hu
Start date: February 1, 2022
Phase:
Study type: Observational

Phenotypic characterization of patients with Hu-Abs, including the different neurological presentation and the presence or not of an underlying cancer. Analysis and clinical correlation of the diagnostic techniques for Hu-Abs detection (immunofluorescence, immunodot/Western blot, and CBA) in serum and/or CSF. Genomic and transcriptomic features of tumors (histological and immune infiltrate characteristics, transcriptomic profile, mutational status).

NCT ID: NCT05744076 Active, not recruiting - Melanoma Clinical Trials

Analysis of Circulating Exosomes in Melanoma Patients

EXOMEL1
Start date: March 1, 2019
Phase:
Study type: Observational

The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.

NCT ID: NCT05742087 Active, not recruiting - Clinical trials for Neurological Diseases or Conditions

Neuropathy and Anti-GFAP Antibodies

Neuro-GFAP
Start date: September 1, 2022
Phase:
Study type: Observational

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts. The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

NCT ID: NCT05741346 Active, not recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Start date: January 18, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to provide continued access to BCX9930 for subjects currently receiving treatment with BCX9930 in a BioCryst-sponsored clinical study for paroxysmal nocturnal hemoglobinuria (PNH) who, in the opinion of the investigator, would benefit from continued treatment with BCX9930 and who do not have access to other treatment options.

NCT ID: NCT05738668 Active, not recruiting - Clinical trials for Anti NMDA Receptor Encephalitis

Clinical-immunological Features of Anti-NMDAR Encephalitis

Bio-NMDAr
Start date: February 1, 2022
Phase:
Study type: Observational

Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers

NCT ID: NCT05734157 Active, not recruiting - Clinical trials for Femoral Artery Occlusion

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery

Start date: February 17, 2022
Phase: N/A
Study type: Interventional

The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.

NCT ID: NCT05731700 Active, not recruiting - In-stent Restenosis Clinical Trials

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

Start date: October 20, 2021
Phase: N/A
Study type: Interventional

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

NCT ID: NCT05729906 Active, not recruiting - Physical Health Clinical Trials

Dynamic Predictions of the Links Between Psychological and Physical Health of Older Patients in Nursing Home

BioMIND
Start date: March 28, 2023
Phase:
Study type: Observational

Taking the older person as a whole is now essential to age well and prevent loss of functional independence. However, the relationship between physical and mental health remains not well understood. Combining the exploration of markers of inflammation, endocrine, nutritional, and metabolic functions, along with long-term monitoring of older persons, could allow for a comprehensive understanding of the biological phenotype, regardless of underlying pathologies. The primary objective will be to simultaneously test the psychosomatic model and the disability model in order to more fully account for the dynamic causal relationships between physical and mental health in older people. The investigators will investigate the mediating role of the biological phenotype on these relationships between mental and physical health. The independent and then combined analysis of specific candidate biomarkers will open up the possibility of identifying a biological mediation between mental and physical health. Furthermore, this will also allow us to deepen our understanding of the evolution of the immune-endocrine-metabolic state and, more broadly, of the biological phenotype of older people during aging.

NCT ID: NCT05728931 Active, not recruiting - Clinical trials for Autoimmune Encephalitis

New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

DeNobio
Start date: January 15, 2022
Phase:
Study type: Observational

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients. The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools.

NCT ID: NCT05728710 Active, not recruiting - Clinical trials for Colorectal Neoplasms

Outcomes of Perforation After Colorectal Endoscopic Submucosal Dissection

Start date: September 1, 2019
Phase:
Study type: Observational [Patient Registry]

Endoscopic resection of superficial colorectal neoplasms decrease risk of colorectal cancer. En bloc resection is necessary for large superficial lesions with risk of superficial submucosal cancer and is advised if feasible for all lesions. Endoscopic submucosal dissection (ESD) allows en bloc resection of large superficial colorectal neoplasms, increasing curative resection rate and decreasing local recurrence risk. However, the risk of perprocedural or delayed perforation is higher compared to wild field piece meal endoscopic mucosal resection. Endoscoping clipping and closing methods mostly allow conservative treatment, but some case still necessitate surgery. The aim of our study is to describe and ananalyse outcomes after perprocedural or delayed perforation in all patients undergoing ESD and analyse the need for surgical intervention.